This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
DiPippo AJ, Patel NK, Barnett CM. Cyclin‐dependent kinase inhibitors for the treatment of breast cancer: past, present, and future. Pharmacotherapy. 2016;36(6):652-67.Search in Google Scholar
Cha C, Ahn SG, Yoo TK, Kim KM, Bae SJ, Yoon C, et al. Local treatment in addition to endocrine therapy in hormone receptor-positive and HER2-negative oligometastatic breast cancer patients: a retrospective multicenter analysis. Breast Care. 2020;15(4):408-14.Search in Google Scholar
Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer. Breast Care. 2016;11(3):167-73.Search in Google Scholar
Curigliano G, Pardo PG, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. The Breast. 2016;28:191-8.Search in Google Scholar
Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, et al. A phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. Clin Cancer Res. 2017;23(10): 2433-41.Search in Google Scholar
Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. The Lancet. 2020;395(10226):817-27.Search in Google Scholar
Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93-115.Search in Google Scholar
Suárez-Arroyo IJ, Loperena-Alvarez Y, Rosario-Acevedo R, Martínez-Montemayor MM. Ganoderma spp.: a promising adjuvant treatment for breast cancer. Medicines. 2017;4(1):15.Search in Google Scholar
Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors Mechanism of Action and Clinical Impact of Ribociclib. Clin Cancer Res. 2017; 23(13):3251-62.Search in Google Scholar
Verheijen RB, Yu H, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017; 102(5):765-76.Search in Google Scholar
van Nuland M, Rosing H, Schellens JH, Beijnen JH. Bioanalytical LC–MS/MS validation of therapeutic drug monitoring assays in oncology. Biomed Chromatogr. 2020;34(1):e4623.Search in Google Scholar
Posocco B, Buzzo M, Poetto AS, Orleni M, Gagno S, Zanchetta M, et al. Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. PloS One. 2020;15(2):e0228822.Search in Google Scholar
Bao X, Wu J, Sanai N, Li J. Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry. J Pharm Biomed Anal. 2019;166:197-204.Search in Google Scholar
Braal CL, Lam MH, Rienks T, van Tilborg CJ, Heuts W, Heijns JB, et al. Quantification of ribociclib in dried blood spots by LC–MS/MS: Method development and clinical validation. J Pharm Biomed Anal. 2021;201:114118.Search in Google Scholar
Turković L, Bočkor L, Ekpenyong O, Silovski T, Lovrić M, Crnković S, et al. Development and validation of a novel LC-MS/MS method for the simultaneous determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A prerequisite for personalized breast cancer treatment. Pharmaceuticals. 2022;15(5):614.Search in Google Scholar
Kamble SN, Munipalli VK, Talapadatur H, Singh RM, Warde S, Nayak S, et al. Development and validation of novel HPLC method for analytical evaluation of Lemborexant in tablet dosage form. GSCARR. 2022;11(1):132-43.Search in Google Scholar
Meesters R, Voswinkel S. Bioanalytical method development and validation: from the USFDA 2001 to the USFDA 2018 guidance for industry. J Appl Bioanal. 2018;4 (3):67-73.Search in Google Scholar
Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, Department of Health & Human Services. 2001:4-10. [ http://www.labcompliance.de/documents/FDA/FDA-Others/Laboratory/f-507bioanalytical-4252fnl.pdf].Search in Google Scholar